Major depressive disorder | cognitive | cognitive science | bipolar disorder | Piaget's theory of cognitive development | obsessive-compulsive disorder | Disorder in the Court | Borderline personality disorder | Bipolar disorder | Substance use disorder | Dissociative identity disorder | Congenital disorder | cognitive psychology | Attention Deficit Hyperactivity Disorder | Vision of Disorder | Social anxiety disorder | Posttraumatic stress disorder | Narcissistic personality disorder | Cognitive | antisocial personality disorder | pervasive developmental disorder | Obsessive–compulsive disorder | Mark Turner (cognitive scientist) | major depressive disorder | Esophageal motility disorder | eating disorder | dissociative identity disorder | conversion disorder | Cognitive Science Society | Cognitive neuroscience |
Cerlapirdine (USAN; SAM-531, WAY-262,531, PF-05212365) is a drug which is under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia.